endoscopic short duration papillary large balloon dilation
DeviceDuring the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
NCT Number: NCT05061680
ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla.
The investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.
Interested in participating?
Request Info18 year–95 year
All sexes
Interventional
Not applicable
Helsinki University Hospital, Helsinki, Finland
This study is planned as a multicenter Scandinavian prospective study including all the patients >18 years with >10mm diameter common bile duct stones visible in cholangiogram. Before ERCP all patient will be informed about this trial, and if they agree to participate this study, they need to give a written informed consent. The endoscopists will decide whether the first step will be large EST and stone extraction or small EST and dilatation. If simple EST does not success, the dilatation will remain as a rescue method. The diameter of dilatation balloon cannot exceed the diameter of common bile duct above the papilla. Cholangiogram is followed when papilla is dilated and the dilatation will be ended when the waist of the papilla disappears. The duration of the dilatation measured, but it does not define the ending of dilatation. All adverse events will be recorded one month and a year after the procedure.
Classification of the patients:
The investigators will collect the information of adverse events such as bleeding, pancreatitis, cholangitis with patient questionnaire as well as from the patient records one month and a year after the procedure
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
Time frame: 30 days
need for additional intervention or need for blood transfusion and hemoglobin drop more than 2 gm/dL
Time frame: 30 days
Plasma amylase rises >3 times the upper limit and newly developed stomach ace more than 24h
Time frame: 30 days
Fever >38
Contact information is provided by the study sponsor or research team.
Leena Kylänpää, MD, PhD
CONTACT
Mia Rainio, MD, PhD
CONTACT
Helsinki University Central Hospital
Other
Endoscopic Papillary Short Duration Large Balloon Dilatation for Removal of Large Bile Duct Stones: a Prospective Multicenter Study of Short and Long-term Adverse Events
Acronym: SHODBADI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738094
Digestive System Diseases, Pancreatic Diseases
São Paulo, Brazil
View Trial DetailsNCT07202559
Chronic Disease, Digestive System Diseases
Baotou, China
View Trial DetailsNCT07267169
Digestive System Diseases, Pancreatic Diseases
Kazan', Russia
View Trial DetailsNCT06729996
Chronic Disease, Diabetes Mellitus
Rochester, Minnesota, United States
View Trial Details